Literature DB >> 9202356

Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.

P Ponikowski1, S D Anker, T P Chua, R Szelemej, M Piepoli, S Adamopoulos, K Webb-Peploe, D Harrington, W Banasiak, K Wrabec, A J Coats.   

Abstract

After acute myocardial infarction, depressed heart rate variability (HRV) has been proven to be a powerful independent predictor of a poor outcome. Although patients with chronic congestive heart failure (CHF) have also markedly impaired HRV, the prognostic value of HRV analysis in these patients remains unknown. The aim of this study was to investigate whether HRV parameters could predict survival in 102 consecutive patients with moderate to severe CHF (90 men, mean age 58 years, New York Heart Association [NYHA] class II to IV, CHF due to idiopathic dilated cardiomyopathy in 24 patients and ischemic heart disease in 78 patients, ejection fraction [EF], 26%; peak oxygen consumption, 16.9 ml/kg/min) after exclusion of patients in atrial fibrilation with diabetes or with chronic renal failure. In the prognostic analysis (Cox proportional-hazards model, Kaplan-Meier survival analysis), the following factors were investigated: age, CHF etiology, NYHA class, EF, peak oxygen consumption, presence of ventricular tachycardia on Holter monitoring, and HRV measures derived from 24-hour electrocardiography monitoring, calculated in the time (standard deviation of all normal RR intervals [SDNN], standard deviation of 5-minute RR intervals [SDANN], mean of all 5-minute standard deviations of RR intervals [SD], root-mean-square of difference of successive RR intervals [rMSSD], and percentage of adjacent RR intervals >50 ms different [pNN50]) and frequency domain (total power [TP], power within low-frequency band [LF], and power within high-frequency band [HF]). During follow-up of 584 +/- 405 days (365 days in all who survived), 19 patients (19%) died (mean time to death: 307 +/- 315 days, range 3 to 989). Cox's univariate analysis identified the following factors to be predictors of death: NYHA (p = 0.003), peak oxygen consumption (p = 0.01), EF (p = 0.02), ventricular tachycardia on Holter monitoring (p = 0.05), and among HRV measures: SDNN (p = 0.004), SDANN (p = 0.003), SD (p = 0.02), and LF (p = 0.003). In multivariate analysis, HRV parameters (SDNN, SDANN, LF) were found to predict survival independently of NYHA functional class, EF, peak oxygen consumption, and ventricular tachycardia on Holter monitoring. The Kaplan-Meier survival curves revealed SDNN < 100 ms to be a useful risk factor; 1-year survival in patients with SDNN < 100 ms was 78% when compared with 95% in those with SDNN > 100 ms (p = 0.008). The coexistence of SDNN < 100 ms and a peak oxygen consumption < 14 ml/kg/min allowed identification of a group of 18 patients with a particularly poor prognosis (1-year survival 63% vs 94% in the remaining patients, p <0.001). We conclude that depressed HRV on 24-hour ambulatory electrocardiography monitoring is an independent risk factor for a poor prognosis in patients with CHF. Whether analysis of HRV could be recommended in the risk stratification for better management of patients with CHF needs further investigation.

Entities:  

Mesh:

Year:  1997        PMID: 9202356     DOI: 10.1016/s0002-9149(97)00215-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  99 in total

Review 1.  Improvements in heart rate variability with exercise therapy.

Authors:  Faye S Routledge; Tavis S Campbell; Judith A McFetridge-Durdle; Simon L Bacon
Journal:  Can J Cardiol       Date:  2010 Jun-Jul       Impact factor: 5.223

2.  Is heart rate variability a valid parameter to predict sudden death in patients with Becker's muscular dystrophy?

Authors:  E Ammendola; V Russo; L Politano; L Santangelo; R Calabrò
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

3.  [Not Available].

Authors:  H D Esperer; S Grund; A Auricchio; E Hecht; D Polywka; J C Geller; W M Hartung; H U Klein
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1998-02

Review 4.  [Percutaneous aortic valve replacement - pro].

Authors:  Lutz Buellesfeld; Eberhard Grube
Journal:  Herz       Date:  2009-03       Impact factor: 1.443

Review 5.  Mechanisms by which exercise training benefits patients with heart failure.

Authors:  Ettore Crimi; Louis J Ignarro; Francesco Cacciatore; Claudio Napoli
Journal:  Nat Rev Cardiol       Date:  2009-04       Impact factor: 32.419

6.  CANONICAL CORRELATION ANALYSIS BETWEEN TIME SERIES AND STATIC OUTCOMES, WITH APPLICATION TO THE SPECTRAL ANALYSIS OF HEART RATE VARIABILITY.

Authors:  Robert T Krafty; Martica Hall
Journal:  Ann Appl Stat       Date:  2013-03-01       Impact factor: 2.083

7.  Do the deceleration/acceleration capacities of heart rate reflect cardiac sympathetic or vagal activity? A model study.

Authors:  Qing Pan; Gongzhan Zhou; Ruofan Wang; Guolong Cai; Jing Yan; Luping Fang; Gangmin Ning
Journal:  Med Biol Eng Comput       Date:  2016-04-08       Impact factor: 2.602

8.  Modeling autonomic regulation of cardiac function and heart rate variability in human endotoxemia.

Authors:  Jeremy D Scheff; Panteleimon D Mavroudis; Steven E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  Physiol Genomics       Date:  2011-06-14       Impact factor: 3.107

9.  Heart rate variability during and after peripheral blood stem cell leukapheresis in autologous transplant patients and allogeneic transplant donors.

Authors:  Takahiko Nakane; Hirohisa Nakamae; Hideo Koh; Mika Nakamae; Ran Aimoto; Yoshiki Terada; Ki-Ryang Koh; Takahisa Yamane; Masayuki Hino
Journal:  Int J Hematol       Date:  2010-03-12       Impact factor: 2.490

10.  Heart rate turbulence for guiding electric therapy in patients with cardiac failure.

Authors:  Giovanni Fazio; Filippo M Sarullo; Luciana D'Angelo; Monica Lunetta; Claudia Visconti; Gabriele Di Gesaro; Loredana Sutera; Giuseppina Novo; Salvatore Novo
Journal:  J Clin Monit Comput       Date:  2010-01-16       Impact factor: 2.502

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.